Inactive/Delisted stock

Panbela Therapeutics Stock (NASDAQ:PBLA)


Chart

Previous Close

$0.16

52W Range

$0.15 - $1.11

50D Avg

$0.25

200D Avg

$0.33

Market Cap

$767.06K

Avg Vol (3M)

$13.42K

Beta

1.26

Div Yield

-

PBLA Company Profile


Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

7

IPO Date

Jan 03, 2017

Website

PBLA Performance


Latest Earnings Call Transcripts


Q2 22Aug 15, 22 | 7:25 PM
Q1 22May 14, 22 | 3:05 PM
Q4 21Mar 24, 22 | 6:31 PM